We Offer Worldwide Shipping
Login Wishlist

Hydroxyphenethylanisate, 4-

$896

  • Brand : BIOFRON

  • Catalogue Number : BD-P0108

  • Specification : 99.0%(HPLC)

  • CAS number : 87932-34-1

  • Formula : C16H16O4

  • Molecular Weight : 272.3

  • PUBCHEM ID : 14704104

  • Volume : 25mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0108

Analysis Method

HPLC,NMR,MS

Specification

99.0%(HPLC)

Storage

2-8°C

Molecular Weight

272.3

Appearance

Powder

Botanical Source

Structure Type

Phenols

Category

SMILES

COC1=CC=C(C=C1)C(=O)OCCC2=CC=C(C=C2)O

Synonyms

2-(4-hydroxyphenyl)ethyl 4-methoxybenzoate

IUPAC Name

2-(4-hydroxyphenyl)ethyl 4-methoxybenzoate

Applications

Density

1.199±0.06 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

165.4±18.1 °C

Boiling Point

446.5±30.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C16H16O4/c1-19-15-8-4-13(5-9-15)16(18)20-11-10-12-2-6-14(17)7-3-12/h2-9,17H,10-11H2,1H3

InChl Key

DSMAYKYXHOGICG-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:87932-34-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27595733

Abstract

Background
The purpose of this study was to examine racial and socio-economic differences in the receipt of laparoscopic or open surgery among patients with colorectal cancer, and to determine if racial and socio-economic differences exist in post-surgical complications, in-hospital mortality and hospital length of stay among patients who received surgery.

Methods
We conducted a cross-sectional analysis of hospitalized patients with a primary diagnosis of colorectal cancer between 2007 and 2011 using data from Nationwide Inpatient Sample. ICD-9 codes were used to capture primary diagnosis, surgical procedures, and health outcomes during hospitalization. We used logistic regression analysis to determine racial and socio-economic predictors of surgery type, post-surgical complications and mortality, and linear regression analysis to assess hospital length of stay.

Results
A total of 122,631 patients were admitted with a primary diagnosis of malignant colorectal cancer between 2007 and 2011. Of these, 17,327 (14.13 %) had laparoscopic surgery, 70,328 (57.35 %) received open surgery, while 34976 (28.52 %) did not receive any surgery. Black (36 %) and Hispanic (34 %) patients were more likely to receive no surgery compared with Whites (27 %) patients. However, among patients that received any surgery, there were no racial differences in which surgery was received (laparoscopic versus open, p = 0.2122), although socio-economic differences remained, with patients from lower residential income areas significantly less likely to receive laparoscopic surgery compared with patients from higher residential income areas (OR: 0.74, 95 % CI: 0.70-0.78). Among patients who received any surgery, Black patients (OR = 1.07, 95 % CI: 1.01-1.13), and patients with Medicare (OR = 1.16, 95 % CI: 1.11-1.22) and Medicaid (OR = 1.15, 95 % CI: 1.07-1.25) insurance experienced significantly higher post-surgical complications, in-hospital mortality (Black OR = 1.18, 95 % CI: 1.00-1.39), and longer hospital stay (Black β = 1.33, 95 % CI: 1.16-1.50) compared with White patients or patients with private insurance.

Conclusion
Racial and socio-economic differences were observed in the receipt of surgery and surgical outcomes among hospitalized patients with malignant colorectal cancer in the US.

Title

Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes: analysis of the nationwide inpatient sample

Author

Tomi Akinyemiju,corresponding author1,2 Qingrui Meng,1 and Neomi Vin-Raviv3,4

Publish date

2016

PMID

27846816

Abstract

Background
Colour polymorphisms are common among animal species. When combined with genetic and ecological data, these polymorphisms can be excellent systems in which to understand adaptation and the molecular changes underlying phenotypic evolution. The meadow spittlebug, Philaenus spumarius (L.) (Hemiptera, Aphrophoridae), a widespread insect species in the Holarctic region, exhibits a striking dorsal colour/pattern balanced polymorphism. Although experimental crosses have revealed the Mendelian inheritance of this trait, its genetic basis remains unknown. In this study we aimed to identify candidate genomic regions associated with the colour balanced polymorphism in this species.

Results
By using restriction site-associated DNA (RAD) sequencing we were able to obtain a set of 1,837 markers across 33 individuals to test for associations with three dorsal colour phenotypes (typicus, marginellus, and trilineatus). Single and multi-association analyses identified a total of 60 SNPs associated with dorsal colour morphs. The genome size of P. spumarius was estimated by flow cytometry, revealing a 5.3 Gb genome, amongst the largest found in insects. A partial genome assembly, representing 24% of the total size, and an 81.4 Mb transcriptome, were also obtained. From the SNPs found to be associated with colour, 35% aligned to the genome and 10% to the transcriptome. Our data suggested that major loci, consisting of multi-genomic regions, may be involved in dorsal colour variation among the three dorsal colour morphs analysed. However, no homology was found between the associated loci and candidate genes known to be responsible for coloration pattern in other insect species. The associated markers showed stronger differentiation of the trilineatus colour phenotype, which has been shown previously to be more differentiated in several life-history and physiological characteristics as well. It is possible that colour variation and these traits are linked in a complex genetic architecture.

Conclusions
The loci detected to have an association with colour and the genomic and transcriptomic resources developed here constitute a basis for further research on the genetic basis of colour pattern in the meadow spittlebug P. spumarius.

Electronic supplementary material
The online version of this article (doi:10.1186/s12863-016-0455-5) contains supplementary material, which is available to authorized users.

KEYWORDS

Association study, Colour polymorphism, de novo genome assembly, de novo transcriptome assembly, Meadow spittlebug

Title

Assessing genotype-phenotype associations in three dorsal colour morphs in the meadow spittlebug Philaenus spumarius (L.) (Hemiptera: Aphrophoridae) using genomic and transcriptomic resources

Author

Ana S. B. Rodrigues,corresponding author1 Sara E. Silva,1 Francisco Pina-Martins,1,2 João Loureiro,3 Mariana Castro,3 Karim Gharbi,4 Kevin P. Johnson,5 Christopher H. Dietrich,5 Paulo A. V. Borges,6 Jose A. Quartau,1 Chris D. Jiggins,7 Octavio S. Paulo,#1 and Sofia G. Seabra#1

Publish date

2016

PMID

32461914

Abstract

Aims
To describe discontinuation and adherence to metformin in the United Kingdom.

Methods
This was a retrospective analysis of data from the Clinical Practice Research Datalink database of type 2 diabetes patients aged ≥18 years with ≥1 metformin prescription in 2013. Metformin use was assessed in new and ongoing users, defined, respectively, as not having or having a prescription for metformin in the baseline period. Discontinuation was assessed in all patients and adherence in patients who did not discontinue metformin. Factors predictive of discontinuation and adherence were assessed.

Results
Discontinuation among new and ongoing users was 35.9% and 23.1%, respectively. Among the continuers of metformin treatment, the adherence rate was 40.5% and 44.3% among new and ongoing users, respectively. Among new users, baseline use of DDP-4 inhibitors (HR 1.276) and diabetes duration (HR 1.013) were associated with an increased risk of discontinuation, whereas increased age (HR 0.997), concomitant lipid-lowering therapy (HR 0.956), macrovascular disease (HR 0.952), and chronic kidney disease (HR 0.952) were associated with a decreased risk of discontinuation among ongoing users. Variables positively associated with adherence in both user groups were (HR values for all patients) age (1.021), smoking status (1.188), and baseline comorbidities: chronic kidney disease, depression, dementia, and chronic obstructive pulmonary disease (1.106, 1.192, 2.27, and 1.211, respectively), while obesity (0.936) and HbA1c 8.0-8.9% (0.862; reference <6.5%) were negatively associated with adherence. Conclusions About one-third of patients initiating metformin discontinued within 12 months and fewer than 50% of all patients are adherent to metformin.

KEYWORDS

Discontinuation, Adherence, Type 2 diabetes mellitus, Oral anti-hyperglycemic agents, Drug therapy, Metformin

Title

Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study

Author

Yuexin Tang,a,⁎ Tracey Weiss,a Jinan Liu,a,1 Swapnil Rajpathak,a and Kamlesh Khuntib

Publish date

2020 Jun;